These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37306717)

  • 1. Successful treatment with avacopan (CCX168) in a pediatric patient with C3 glomerulonephritis.
    Zotta F; Diomedi-Camassei F; Gargiulo A; Cappoli A; Emma F; Vivarelli M
    Pediatr Nephrol; 2023 Dec; 38(12):4197-4201. PubMed ID: 37306717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the complement biomarker profile of C3 glomerulopathy.
    Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C3 glomerulonephritis with a severe crescentic phenotype.
    Ravindran A; Fervenza FC; Smith RJH; Sethi S
    Pediatr Nephrol; 2017 Sep; 32(9):1625-1633. PubMed ID: 28593446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children.
    Ueda C; Horinouchi T; Inoki Y; Ichikawa Y; Tanaka Y; Kitakado H; Kondo A; Sakakibara N; Nagano C; Yamamura T; Fujimura J; Kamiyoshi N; Ishimori S; Ninchoji T; Kaito H; Shima Y; Iijima K; Nozu K; Yoshikawa N
    Pediatr Nephrol; 2024 Sep; 39(9):2679-2689. PubMed ID: 38662234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature.
    Fernandez-Ruiz R; Blank RB; Wu M; Belmont HM
    Lupus; 2021 Sep; 30(10):1671-1678. PubMed ID: 34192954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
    Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
    Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
    Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
    Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C3 glomerulopathy and current dilemmas.
    Ito N; Ohashi R; Nagata M
    Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.
    Okuda Y; Ishikura K; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Fukuzawa R; Ogata K; Honda M
    Nephrology (Carlton); 2015 Apr; 20(4):286-92. PubMed ID: 25524631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
    Regunathan-Shenk R; Avasare RS; Ahn W; Canetta PA; Cohen DJ; Appel GB; Bomback AS
    Am J Kidney Dis; 2019 Mar; 73(3):316-323. PubMed ID: 30413277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C3 Glomerulopathy: Pathogenesis and Treatment.
    Ahmad SB; Bomback AS
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):104-110. PubMed ID: 32553242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
    Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
    Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
    Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
    Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of C3 in C3 glomerulopathy.
    Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
    Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
    Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C3 glomerulopathy in a patient with a history of post-infectious glomerulonephritis.
    Nnadi N; Hendricks AR; Torrealba J; Drake KA; Gattineni J
    Pediatr Nephrol; 2024 Mar; 39(3):745-748. PubMed ID: 37874356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
    Caravaca-Fontán F; Trujillo H; Alonso M; Díaz-Encarnación M; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez E; de la Cerda F; Pérez de José A; López I; Fernández L; Pérez Gómez V; Ávila A; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; González F; Shabaka A; Illescas ML; Calvo C; Oviedo V; Da Silva I; Goicoechea de Jorge E; Caravaca F; Praga M;
    Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement gene mutations in children with C3 glomerulopathy: do they affect the response to mycophenolate mofetil?
    Günay N; Dursun İ; Gökçe İ; Akbalık Kara M; Tekcan D; Çiçek N; Torun Bayram M; Koyun M; Dinçel N; Dursun H; Saygılı S; Yürük Yıldırım ZN; Yüksel S; Dönmez O; Yel S; Demircioğlu Kılıç B; Aydoğ Ö; Atmış B; Çaltık Yılmaz A; Bakkaloğlu SA; Aytaç MB; Taşdemir M; Kasap Demir B; Soylu A; Çomak E; Kantar Özşahin A; Kaçar A; Canpolat N; Yılmaz A; Girişgen İ; Akkoyunlu KB; Alpay H; Poyrazoğlu HM
    Pediatr Nephrol; 2024 May; 39(5):1435-1446. PubMed ID: 38041748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C3 glomerulonephritis associated with ANCA positivity: a case report.
    Li L; Liu LQ; Yang YY; Hu ZX
    BMC Nephrol; 2021 Apr; 22(1):143. PubMed ID: 33882866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.